Emergence of Antinuclear Antibodies in Psoriatic Patients Treated with Infliximab: Personal Experience and Literature Review | Zendy

Chimenti Maria Sole | Zendy; Spinelli Francesca Romana | Zendy; Giunta Alessandro | Zendy; Martinelli Francesco | Zendy; Saraceno Rosita | Zendy; Conti Fabrizio | Zendy; Perricone Roberto | Zendy; Valesini Guido | Zendy

Premium

Emergence of Antinuclear Antibodies in Psoriatic Patients Treated with Infliximab: Personal Experience and Literature Review

Author(s) -

Chimenti Maria Sole,

Spinelli Francesca Romana,

Giunta Alessandro,

Martinelli Francesco,

Saraceno Rosita,

Conti Fabrizio,

Perricone Roberto,

Valesini Guido

Publication year - 2014

Publication title -

drug development research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.582

H-Index - 60

eISSN - 1098-2299

pISSN - 0272-4391

DOI - 10.1002/ddr.21198

Subject(s) - infliximab , psoriasis , medicine , anti nuclear antibody , psoriatic arthritis , tumor necrosis factor alpha , etanercept , incidence (geometry) , dermatology , immunology , pathogenesis , antibody , population , gastroenterology , autoantibody , physics , optics , environmental health

Postmarketing Phase IVPsoriasis is a chronic inflammatory skin disease affecting up to 2.5% of the population, with joint involvement in approximately 30% of patients. Given the role of tumor necrosis factor ( TNF ) in the pathogenesis of psoriasis, anti‐ TNF therapies have been developed; several studies have demonstrated the efficacy of infliximab ( IFX ) as induction and maintenance therapy in the treatment of moderate to severe plaque psoriasis. The development of antinuclear antibodies ( ANA ) in anti‐ TNF ‐treated patients has been frequently reported. The aim of this study was to investigate the incidence of ANA and anti‐double stranded DNA (anti‐ds DNA ) antibodies in psoriatic patients receiving IFX . Incidence of new ANA and anti‐ds‐ DNA was 16.2% and 8.1% respectively. No case of anti‐ TNF induced L upus was observed during the follow‐up.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research